Activist Barington Targets Chemed for Strategic Review and Cost Cuts
CHE sits 41% above its 52-week low of $365.205.
Summary
Activist investor Barington Capital is pushing Chemed for a strategic review and cost cuts, per Bloomberg. This is the first known activist campaign at the company, coming just two months after shareholders rejected the executive pay plan—a sign of simmering governance discontent. Chemed trades near its 52-week high with a $6.8B market cap, so the pressure to unlock value through portfolio changes or margin improvement could resonate. The stock has already seen strong buyback activity and a raised guidance this year, but an activist push adds a new catalyst for operational or structural change. Watch for any formal response from Chemed or a potential settlement that could include board seats.
At the time of this announcement, CHE was trading at $515.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $365.21 to $517.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.